Zobrazeno 1 - 10
of 151
pro vyhledávání: '"Anna Maria Fink"'
Autor:
Othman Al-Sawaf, Can Zhang, Hyun Yong Jin, Sandra Robrecht, Yoonha Choi, Sandhya Balasubramanian, Alex Kotak, Yi Meng Chang, Anna Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl-Anton Kreuzer, Brenda Chyla, Joseph N. Paulson, Christian P. Pallasch, Lukas P. Frenzel, Martin Peifer, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)
Abstract Data on long-term outcomes and biological drivers associated with depth of remission after BCL2 inhibition by venetoclax in the treatment of chronic lymphocytic leukemia (CLL) are limited. In this open-label parallel-group phase-3 study, 432
Externí odkaz:
https://doaj.org/article/c127bbfa3a4040329f269c6323da0d06
Autor:
Deyan Yosifov, Julia von Tresckow, Adam Giza, Sandra Robrecht, Christof Schneider, Billy Jebaraj, Daniel Mertens, Matthias Ritgen, Anke Schilhabel, Karl-Anton Kreuzer, Anna Maria Fink, Othman Al-Sawaf, Petra Langerbeins, Kirsten Fischer, Barbara Eichhorst, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer, Paula Cramer, Eugen Tausch
Publikováno v:
HemaSphere, Vol 7, p e14818fb (2023)
Externí odkaz:
https://doaj.org/article/0c09a3bc60ef48cdbb6def7051a40b54
Autor:
Othman Al-Sawaf, Can Zhang, Hyun Yong Jin, Sandra Robrecht, Yoonha Choi, Sandhya Balasubramanian, Alex Kotak, Yi Meng Chang, Anna Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl-Anton Kreuzer, Brenda Chyla, Joseph N. Paulson, Christian P. Pallasch, Lukas P. Frenzel, Martin Peifer, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/c77836ed356f4db6a5fa3d2f59504785
Autor:
Nadine Kutsch, Jasmin Bahlo, Sandra Robrecht, Jeremy Franklin, Can Zhang, Christian Maurer, Nisha De Silva, Elisabeth Lange, Rudolf Weide, Michael G. Kiehl, Martin Sökler, Rudolf Schlag, Ursula Vehling-Kaiser, Georg Köchling, Christoph Plöger, Michael Gregor, Torben Plesner, Marco Herling, Kirsten Fischer, Hartmut Döhner, Michael Kneba, Clemens-Martin Wendtner, Wolfram Klapper, Karl-Anton Kreuzer, Sebastian Böttcher, Stephan Stilgenbauer, Anna Maria Fink, Michael Hallek, Barbara Eichhorst
Publikováno v:
HemaSphere, Vol 4, Iss 1, p e336 (2020)
Abstract. Fludarabine, cyclophosphamide and rituximab (FCR) was compared to bendamustine and rituximab (BR) in an international, randomized, open label, phase 3 trial in 561 previously untreated, fit patients with chronic lymphocytic leukemia (CLL) w
Externí odkaz:
https://doaj.org/article/9ab624e05ae342d4ae618cb2980e0b9d
Autor:
Sibylle C. Mellinghoff, Leonie Mayer, Sandra Robrecht, Leonie M. Weskamm, Christine Dahlke, Henning Gruell, Maike Schlotz, Kanika Vanshylla, Hans A. Schloser, Martin Thelen, Anna-Maria Fink, Kirsten Fischer, Florian Klein, Marylyn M. Addo, Barbara Eichhorst, Michael Hallek, Petra Langerbeins
Publikováno v:
Haematologica, Vol 107, Iss 10 (2022)
Externí odkaz:
https://doaj.org/article/05ba2f11c8a84d01b9218e99cc55c62f
Autor:
Nadine Kutsch, Christian Pallasch, Eugen Tausch, Volkmar Böhme, Matthias Ritgen, Rüdiger Liersch, Alexander Wacker, Georg Jacobs, Ralf Ulrich Trappe, Peter Dreger, Kirsten Fischer, Anna-Maria Fink, Stephan Stilgenbauer, Shuyan Zhai, Biao Li, Juliane M. Jürgensmeier, Nishanthan Rajakumaraswamy, Pankaj Bhargava, Michael Hallek, Barbara F. Eichhorst
Publikováno v:
HemaSphere, Vol 6, Iss 4, p e692 (2022)
Externí odkaz:
https://doaj.org/article/cc1dd22b903a4e9bb9d8ee19e48800b6
Autor:
Nadine, Kutsch, Emily Eva, Holmes, Sandra, Robrecht, Gudrun, Schüler, Ursula, Vehling-Kaiser, Thomas, Decker, Sigrun, Müller-Hagen, Karin, Heinisch, Sebastian, Böttcher, Matthias, Ritgen, Karl-Anton, Kreuzer, Stephan, Stilgenbauer, Anna Maria, Fink, Kirsten, Fischer, Barbara, Eichhorst, Michael, Hallek, Clemens-Martin, Wendtner
Publikováno v:
Leukemia & Lymphoma. 64:478-482
Autor:
Paula Cramer, Julia v. Tresckow, Sandra Robrecht, Jasmin Bahlo, Moritz Fürstenau, Petra Langerbeins, Natali Pflug, Othman Al-Sawaf, Werner J. Heinz, Ursula Vehling-Kaiser, Jan Dürig, Eugen Tausch, Manfred Hensel, Stephanie Sasse, Anna-Maria Fink, Kirsten Fischer, Karl-Anton Kreuzer, Sebastian Böttcher, Matthias Ritgen, Michael Kneba, Clemens-Martin Wendtner, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek
Publikováno v:
Haematologica, Vol 106, Iss 2 (2020)
The introduction of targeted agents has revolutionized the treatment of chronic lymphocytic leukemia but only few patients achieve complete remissions and minimal residual disease negativity with ibrutinib monotherapy. This multicenter, investigator-
Externí odkaz:
https://doaj.org/article/2ca066e2adef4fddaa1e0e1cd1ae9f54
Autor:
Paula, Cramer, Moritz, Fürstenau, Sandra, Robrecht, Adam, Giza, Can, Zhang, Anna-Maria, Fink, Kirsten, Fischer, Petra, Langerbeins, Othman, Al-Sawaf, Eugen, Tausch, Christof, Schneider, Johannes, Schetelig, Peter, Dreger, Sebastian, Böttcher, Karl-Anton, Kreuzer, Anke, Schilhabel, Matthias, Ritgen, Monika, Brüggemann, Michael, Kneba, Stephan, Stilgenbauer, Barbara, Eichhorst, Michael, Hallek
Publikováno v:
The Lancet Haematology. 9:e745-e755
Although BTK inhibitors provide long-term disease-control in patients with chronic lymphocytic leukaemia, they need to be combined with BCL2 inhibitors or antibodies to achieve deep responses with undetectable minimal residual disease (uMRD), which a
Autor:
Barbara Eichhorst, Carsten U. Niemann, Arnon P. Kater, Moritz Fürstenau, Julia von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindström, Caspar da Cunha-Bang, Christof Schneider, Christian B. Poulsen, Thomas Illmer, Björn Schöttker, Thomas Nösslinger, Ann Janssens, Ilse Christiansen, Michael Baumann, Henrik Frederiksen, Marjolein van der Klift, Ulrich Jäger, Maria B.L. Leys, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry Koene, Lisbeth Enggaard, Jereon Goede, Josien C. Regelink, Anouk Widmer, Florian Simon, Nisha De Silva, Anna-Maria Fink, Jasmin Bahlo, Kirsten Fischer, Clemens-Martin Wendtner, Karl A. Kreuzer, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Mark-David Levin, Marinus van Oers, Christian Geisler, Stephan Stilgenbauer, Michael Hallek
Publikováno v:
Eichhorst, B, Niemann, C U, Kater, A P, Fürstenau, M, von Tresckow, J, Zhang, C, Robrecht, S, Gregor, M, Juliusson, G, Thornton, P, Staber, P B, Tadmor, T, Lindström, V, da Cunha-Bang, C, Schneider, C, Poulsen, C B, Illmer, T, Schöttker, B, Nösslinger, T, Janssens, A, Christiansen, I, Baumann, M, Frederiksen, H, van der Klift, M, Jäger, U, Leys, M B L, Hoogendoorn, M, Lotfi, K, Hebart, H, Gaska, T, Koene, H, Enggaard, L, Goede, J, Regelink, J C, Widmer, A, Simon, F, De Silva, N, Fink, A-M, Bahlo, J, Fischer, K, Wendtner, C-M, Kreuzer, K A, Ritgen, M, Brüggemann, M, Tausch, E, Levin, M-D, van Oers, M, Geisler, C, Stilgenbauer, S, Hallek, M, German CLL Study Group (GCLLSG), Haemato-Oncology Foundation for Adults in the Netherlands (HOVON), Nordic CLL Study Groups, Swiss Group for Clinical Cancer Research (SAKK), The Israeli CLL Association & Cancer Trials Ireland 2023, ' First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia ', The New England Journal of Medicine, vol. 388, no. 19, pp. 1739-1754 . https://doi.org/10.1056/NEJMoa2213093
BACKGROUNDRandomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking.METHODSIn a phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57065540dd32adf0cc1d031449d13807
https://vbn.aau.dk/da/publications/3cae35e7-c81b-42b3-8598-001ac74af83e
https://vbn.aau.dk/da/publications/3cae35e7-c81b-42b3-8598-001ac74af83e